Skip to main content

Advertisement

Table 1 Echocardiographic analysis (baseline) of Con and p85-KO mouse hearts

From: Ouabain prevents pathological cardiac hypertrophy and heart failure through activation of phosphoinositide 3-kinase α in mouse

  BW (g) HR (bpm) EDA (cm2) ESA (cm2) PWT (cm) SWT (cm) RWT MPI FS LV mass (g)
Con 31.8 ± 1.2 439 ± 9 0.168 ± 0.004 0.088 ± 0.003 0.114 ± 0.003 0.104 ± 0.003 0.60 ± 0.02 0.36 ± 0.03 0.45 ± 0.02 0.126 ± 0.004
KO 28.4 ± 1.0 438 ± 11 0.153 ± 0.004* 0.081 ± 0.004 0.108 ± 0.005 0.087 ± 0.002* 0.54 ± 0.02 0.30 ± 0.02 0.45 ± 0.01 0.105 ± 0.005*
  1. The p85-KO and the Cre controls (12–16 week-old, male) were subjected to echocardiography analysis
  2. BW body weight; HR heart rate; EDA end diastolic area; ESA end systolic area; PWT posterior wall thickness; SWT septal wall thickness; RWT relative wall thickness; MPI myocardial performance index; FS fractioning shortening; LV mass left ventricular mass; Con n = 21; KO n = 15
  3. * p < 0.05 v.s. Con